PDCD1 and cancer: In particular, immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) and its ligand PD-L1, have to date been approved by the U.S. Food and Drug Administration (FDA) for the use in the treatment of patients with 10 distinct cancer types5.